San Antonio Breast Cancer Symposium

Tamoxifen or Anastrozole for DCIS? Age and Symptom Profiles Matter

Tamoxifen and anastrozole are similarly effective in preventing breast cancer recurrence in postmenopausal women with ductal carcinoma in situ (DCIS). The choice depends on patient preferences, side effect profiles, age, and other patient factors, according to separate studies presented at the 2015 San Antonio Breast Cancer Symposium.In the large, placebo-controlled [ Read More ]

Benefit for T-DM1 Confirmed

The antibody-drug conjugate trastuzumab emtansine (T-DM1) improved overall survival (OS) compared with physician’s choice of therapy for patients with pretreated HER2-positive metastatic breast cancer, according to final results from the phase 3 TH3RESA trial. The study was supported by Roche.Treatment with T-DM1 led to a clinically meaningful and statistically significant [ Read More ]

Omit Chemotherapy for Premenopausal Luminal A Breast Cancer?

Younger patients with luminal A subtype breast cancer may not need chemotherapy, according to a Danish trial presented at the 2015 San Antonio Breast Cancer Symposium. Luminal A biological subtype breast cancer has an excellent prognosis, even in high-risk patients, the study suggests.“A large body of evidence suggests that luminal [ Read More ]

Early Results with Immunotherapy in Breast Cancer

Immunotherapy is a hot topic in cancer right now, with approved checkpoint inhibitors for melanoma and non–small cell lung cancer. Checkpoint inhibitors are also making inroads in other solid tumors.Separate preliminary studies of checkpoint inhibitors in the treatment of breast cancer had less impressive results, but these are early studies, [ Read More ]

ESR1 Mutations Portend Worse Survival in ER+ Advanced Breast Cancer

A “liquid biopsy” was able to detect 2 mutations in the estrogen receptor 1 (ESR1) gene that predicted worse overall survival (OS) in women with estrogen receptor–positive (ER+), metastatic breast cancer who were originally enrolled in the BOLERO-2 clinical trial.The presence of a D358G and/or Y537S mutation in the ESR1 [ Read More ]

Sign me up!